Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection

Imagem de Miniatura
Arquivos
art_MORALES_Vaginal_Microbiome_Components_as_Correlates_of_Cervical_Human_2022.PDF (548.09 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
MORALES, Julia Andrade Pessoa
MARCONI, Camila
EL-ZEIN, Mariam
RAVEL, Jacques
PINTO, Gabriel Victor da Silva
SILVEIRA, Rosana
LIMA, Moises Diogo de
CARVALHO, Newton Sergio de
ALVES, Rosane Ribeiro Figueiredo
PARADA, Cristina Maria Garcia de Lima
Citação
JOURNAL OF INFECTIOUS DISEASES, v.226, n.6, p.1084-1097, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Interplay between vaginal microbiome and human papillomavirus (HPV) remains unclear, partly due to heterogeneity of microbiota. Methods We used data from 546 women enrolled in a cross-sectional study in 5 Brazil. We genotyped vaginal samples for HPV and sequenced V3-V4 region of 16S rRNA gene for vaginal microbiome analysis. We used stepwise logistic regression to construct 2 linear scores to predict high-risk HPV (hrHPV) positivity: one based exclusively on presence of individual bacterial taxa (microbiome-based [MB] score) and the other exclusively on participants' sociodemographic, behavioral, and clinical (SBC) characteristics. MB score combined coefficients of 30 (of 116) species. SBC score retained 6 of 25 candidate variables. We constructed receiver operating characteristic curves for scores as hrHPV correlates and compared areas under the curve (AUC) and 95% confidence intervals (CI). Results Overall, prevalence of hrHPV was 15.8%, and 26.2% had a Lactobacillus-depleted microbiome. AUCs were 0.8022 (95% CI, .7517-.8527) for MB score and 0.7027 (95% CI, .6419-.7636) for SBC score (P = .0163). Conclusions The proposed MB score is strongly correlated with hrHPV positivity-exceeding the predictive value of behavioral variables-suggesting its potential as an indicator of infection and possible value for clinical risk stratification. This cross-sectional study demonstrated a strong correlation between vaginal microbiome components and cervical high-risk HPV positivity.
Palavras-chave
vaginal microbiome, HPV infection, high-risk HPV, 16S RNA sequencing
URI
https://observatorio.fm.usp.br/handle/OPI/50490
Referências
  1. Austin MN, 2015, ANAEROBE, V32, P37, DOI 10.1016/j.anaerobe.2014.12.003
  2. Brotman RM, 2014, J INFECT DIS, V210, P1723, DOI 10.1093/infdis/jiu330
  3. Brusselaers N, 2019, AM J OBSTET GYNECOL, V221, P9, DOI 10.1016/j.ajog.2018.12.011
  4. Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679
  5. Ceccarani C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50410-x
  6. Chen YL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4279-6
  7. Colpani V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229154
  8. Dareng EO, 2016, EPIDEMIOL INFECT, V144, P123, DOI 10.1017/S0950268815000965
  9. Denslow SA, 2011, INT J GYNECOL OBSTET, V114, P273, DOI 10.1016/j.ijgo.2011.03.011
  10. Di Paola M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09842-6
  11. Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
  12. Engberts MK, 2007, CANCER CYTOPATHOL, V111, P269, DOI 10.1002/cncr.22947
  13. Fadrosh DW, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-6
  14. Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
  15. Fettweis JM, 2019, NAT MED, V25, P1012, DOI 10.1038/s41591-019-0450-2
  16. Franco EL, 1997, CANCER EPIDEM BIOMAR, V6, P759
  17. Gajer P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003605
  18. Gallo MF, 2012, ANN EPIDEMIOL, V22, P213, DOI 10.1016/j.annepidem.2011.11.005
  19. Huang XJ, 2018, INT J CANCER, V143, P621, DOI 10.1002/ijc.31342
  20. King Caroline C, 2011, Infect Dis Obstet Gynecol, V2011, P319460, DOI 10.1155/2011/319460
  21. Kuczynski Justin, 2012, Curr Protoc Microbiol, VChapter 1, DOI [10.1002/0471250953.bi1007s36, 10.1002/9780471729259.mc01e05s27]
  22. Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
  23. Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018
  24. Marconi C, 2020, SEX TRANSM DIS, V47, P562, DOI 10.1097/OLQ.0000000000001204
  25. Marconi C, 2015, INT J GYNECOL OBSTET, V131, P137, DOI 10.1016/j.ijgo.2015.05.016
  26. Marconi C, 2014, J LOW GENIT TRACT DI, V18, P261, DOI 10.1097/LGT.0000000000000003
  27. McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139
  28. Mirmonsef Paria, 2014, PLoS One, V9, pe102467, DOI 10.1371/journal.pone.0102467
  29. Mitra A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15856-y
  30. Moscicki AB, 2010, CANCER EPIDEM BIOMAR, V19, P2055, DOI 10.1158/1055-9965.EPI-10-0394
  31. Muzny CA, 2019, J INFECT DIS, V220, P1399, DOI 10.1093/infdis/jiz342
  32. Norenhag J, 2020, BJOG-INT J OBSTET GY, V127, P171, DOI 10.1111/1471-0528.15854
  33. NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
  34. Onywera H, 2019, PAPILLOMAVIRUS RES, V7, P154, DOI 10.1016/j.pvr.2019.04.006
  35. Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
  36. Reimers LL, 2016, J INFECT DIS, V214, P1361, DOI 10.1093/infdis/jiw374
  37. RILEY DE, 1992, J CLIN MICROBIOL, V30, P465, DOI 10.1128/JCM.30.2.465-472.1992
  38. Shaw E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1446-x
  39. Ferreira CST, 2015, SAO PAULO MED J, V133, P465, DOI 10.1590/1516-3180.2014.9182710
  40. Thomas AM, 2019, NAT MED, V25, P1948, DOI 10.1038/s41591-019-0663-4
  41. Usyk M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008376
  42. Wang HY, 2019, J INFECT DIS, V220, P1243, DOI 10.1093/infdis/jiz325
  43. Watts DH, 2005, J INFECT DIS, V191, P1129, DOI 10.1086/427777
  44. Yang Q, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00286

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24